Not all body fat is created equal. Visceral fat — the fat that wraps around your organs — is metabolically active in ways that subcutaneous fat is not. It drives inflammation, insulin resistance, and cardiovascular risk out of proportion to how it looks on the outside.
Tesamorelin is the only GHRH analog with FDA approval specifically for reducing visceral fat. That makes it a uniquely valuable peptide for patients whose midsection is not responding to training or diet alone.
How Tesamorelin Works
Like sermorelin and CJC-1295, tesamorelin is a GHRH analog. It stimulates the pituitary to release your own growth hormone in a natural pulsatile pattern. Where it stands apart is potency and effect distribution: the growth hormone release it triggers appears to preferentially mobilize visceral adipose tissue.
In pivotal clinical trials, tesamorelin reduced visceral adipose tissue by roughly 15 to 18% over 26 weeks — a change large enough to meaningfully lower cardiometabolic risk markers.
The Cognitive Angle
A separate line of research has explored tesamorelin for cognitive function in older adults. Trials in adults with mild cognitive impairment have shown improvements in executive function and verbal memory over 20 weeks of use.
The mechanism appears to be a combination of increased IGF-1 (a growth factor important to brain health) and improved metabolic function. This is not a treatment for diagnosed cognitive disease, but for high-functioning adults noticing subtle age-related declines, the data is compelling.
Who Should Consider It
Tesamorelin is a strong fit for adults with persistent visceral fat despite reasonable training and nutrition, patients with metabolic syndrome, adults in their 40s and 50s who want a growth hormone protocol with a more targeted metabolic profile, and patients who prioritize cognitive resilience alongside physical performance.
It is not appropriate for anyone with active cancer, uncontrolled pituitary disorders, or during pregnancy.
Dosing and Cycles
Typical protocols use 1 to 2 mg daily via subcutaneous injection, cycled over 12 to 26 weeks with monitoring of IGF-1 and metabolic markers. Because tesamorelin is more potent than sermorelin, cycles are usually shorter and more targeted.
Body composition and waist measurement should be tracked in addition to weight — the point is where the fat is coming off, not just the scale number.
The Bottom Line
Tesamorelin is not the right peptide for every patient. But when the goal is targeted visceral fat reduction and cognitive resilience, it is one of the most evidence-backed tools available. Summit clinicians recommend it as part of a broader protocol — not as a standalone shortcut.
Target Visceral Fat the Right Way
See if a tesamorelin protocol fits your labs, your goals, and your budget.
Start Your Consultation